CSL 111: potential in ACS not yet ERASEd

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1586, 2007-01, pp. : 7-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibitors of 5-lipoxygenase: a therapeutic potential yet to be fully realized?

By Young R.N.

European Journal of Medicinal Chemistry, Vol. 34, Iss. 9, 1999-09 ,pp. : 671-685

Elsevier

Access to resources Recommend Favorite

GLP-1-based therapies yet to reach their peak potential

Inpharma, Vol. 1, Iss. 1656, 2008-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Abciximab: benefits for some in ACS

Inpharma, Vol. 1, Iss. 1535, 2006-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Bivalirudin prevails for diabetics with ACS

Inpharma, Vol. 1, Iss. 1636, 2008-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Statins - early administration best in ACS

Inpharma, Vol. 1, Iss. 1267, 2000-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite